Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2183 - Impact of adding ramucirumab to paclitaxel in patients with advanced gastric cancer according to the level of ascites: A multicenter retrospective study

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Clinical Research;  Immunotherapy

Tumour Site

Gastric Cancer

Presenters

Toshiki Masuishi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

T. Masuishi1, S. Kadowaki2, H. Hirano3, S. Kawai4, T. Yamada5, T. Moriwaki5, N. Machida6, N. Boku7, K. Muro1

Author affiliations

  • 1 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 2 Department Of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya/JP
  • 3 Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 5 Division Of Gastroenterology, Faculty Of Medicine, University of Tsukuba, Tsukuba/JP
  • 6 Division Of Gastrointestinal Oncology, Shizuoka Cancer Center, 4118777 - Shizuoka/JP
  • 7 Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo/JP
More

Resources

Abstract 2183

Background

Adding ramucirumab (Ram) to paclitaxel (PTX) improved the overall survival (OS) in patients with advanced gastric cancer (AGC) in the RAINBOW trial, which excluded patients with high levels of ascites.

Methods

This retrospective study included patients with AGC who received PTX alone or PTX+Ram as a 2nd-line treatment from Nov. 2013 to Nov. 2016. Selection criteria were ECOG PS of 0–2, refractory or intolerant to fluoropyrimidines, and no prior use of taxane or Ram. The level of ascites was classified as low (no or limited to either the pelvic cavity or upper abdomen) or high (extended from the pelvic cavity to the upper abdomen). An adjusted HR (aHR) for progression-free survival (PFS) and OS was calculated by a multivariate Cox model that contained variables with p < 0.05 in the univariate analysis to reduce imbalance between both treatments.

Results

Among 305 patients, 201 (PTX/PTX+Ram, 115/86) and 104 patients (PTX/PTX+Ram, 63/41) were classified into the low and high ascites groups, respectively. There were no significant differences in the baseline characteristics between PTX and PTX+Ram in either group, excepting the proportion of patients with PS of 2 (PTX/PTX+Ram, 18/9% and 24/10% in the low and high groups, respectively) and high ALP levels (PTX/PTX+Ram, 36/23% in the low group). The median PFS in PTX/PTX+Ram was 3.0/5.2 months (m) (HR 0.56, 95%CI 0.42–0.75, p < 0.0001; aHR 0.59, 95%CI 0.44–0.79, p = 0.0004) in the low group and 2.2/3.5 m (HR 0.61, 95%CI 0.40–0.92, p = 0.02; aHR 0.57, 95%CI 0.42–0.77, p = 0.0003) in the high group, and the median OS was 6.9/10.6 m (HR 0.67, 95%CI 0.48–0.93, p = 0.02; aHR 0.69, 95%CI 0.49–0.97, p = 0.03) in the low group and 4.8/6.2 m (HR 0.57, 95%CI 0.37–0.88, p = 0.01; aHR 0.64, 95%CI 0.40–0.99, p = 0.046) in the high group. The incidence of febrile neutropenia was not different between PTX (3%) and PTX+Ram (3%) in the low group but was higher in PTX+Ram (12%) than in PTX (3%) in the high group.

Conclusions

Our study suggests that adding Ram to PTX may prolong survival in patients with AGC, regardless of the level of ascites. However, there is a risk of febrile neutropenia when administering PTX+Ram to patients with a high level of ascites.

Clinical trial identification

Legal entity responsible for the study

Shigenori Kadowaki.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

T. Masuishi, N. Boku, K. Muro: Honoraria: Lilly S. Kadowaki: Research funding: Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.